12:00 AM
Jun 01, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Letairis ambrisentan: Phase III data

Data from the open-label, single-arm Phase III ARIES-3 trial in 224 patients showed that 5 mg Letairis ambrisentan once daily met the primary endpoint with a mean 21 m improvement from baseline in 6MWD at 24 weeks (p<0.001)....

Read the full 166 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >